Summary:

- Sangamo Therapeutics, a leading genomic medicine company, has announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for ST-503, a potential treatment for idiopathic small fiber neuropathy (iSFN), a type of chronic neuropathic pain.

- ST-503 is a gene therapy candidate that aims to address the underlying genetic causes of iSFN by delivering a functional gene to restore normal nerve function and alleviate chronic pain symptoms.

- The clearance of the IND application allows Sangamo to proceed with clinical trials to evaluate the safety and efficacy of ST-503 in patients with iSFN, representing a significant milestone in the development of a new therapeutic approach for this debilitating condition.